Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

NCT05104281 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: osimertinib oral and bevazizumab intravenously

Sponsor

Qingdao Central Hospital